AOD-9604
AOD-9604
Also known as: AOD9604, Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
Overview
Key Facts
Primary Goal: A modified fragment of human growth hormone (amino acids 177-191) with an added tyrosine at the N-terminus
A modified fragment of human growth hormone (amino acids 177-191) with an added tyrosine at the N-terminus. It was developed to isolate the fat-metabolizing activity of GH without its growth-promoting or diabetogenic effects. Half-Life ~30 minutes Typical Dose 250–500 mcg Frequency once daily, fasted Cycle Length 12-24 weeks
Dosing Information
Half-Life
~30 minutes
Typical Dose
250–500 mcg
Frequency
once daily, fasted
Cycle Length
12-24 weeks
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
AOD-9604 underwent Phase II clinical trials for obesity showing modest but statistically significant fat loss compared to placebo. It received GRAS (Generally Recognized as Safe) status from the FDA in 2014 for use as a food substance. Recent research has pivoted toward its potential in cartilage regeneration and osteoarthritis treatment.
Frequently Asked Questions
Common questions about AOD-9604
UK-Specific Information
Exclusive data points and guidance for UK residents using AOD-9604
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.